Plasma-Derived Exosomal Circular RNA hsa_circ_0005540 as a Novel Diagnostic Biomarker for Coronary Artery Disease
Autor: | Yan-Hong Pan, Can Chen, Lei Zheng, Meng-yun Cai, Xing-dong Xiong, Xinguang Liu, Wei-Peng Wu, Jin-Ming Cen |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Adult
Male Oncology medicine.medical_specialty Medicine (General) Article Subject Clinical Biochemistry Coronary Artery Disease Exosomes Discriminatory power Coronary artery disease Framingham Heart Study R5-920 Circular RNA Internal medicine Genetics medicine Humans Diagnostic biomarker Molecular Biology Aged Plasma samples Sequence Analysis RNA Plasma derived business.industry Gene Expression Profiling Biochemistry (medical) High-Throughput Nucleotide Sequencing RNA Circular General Medicine Middle Aged medicine.disease Microvesicles Up-Regulation Early Diagnosis Case-Control Studies Female business Biomarkers Research Article |
Zdroj: | Disease Markers, Vol 2020 (2020) Disease Markers |
ISSN: | 1875-8630 0278-0240 |
Popis: | Background. Exosomes exist in almost all body fluid and contain diverse biological contents which may be reflective of disease state. Circular RNAs (circRNAs) are stable in structure and have a long half-life in exosomes without degradation, thus making them reliable biomarkers. However, the potential of exosomal circRNAs as biomarkers of coronary artery disease (CAD) remains to be established. Here, we aimed to investigate the expression levels and the potential use of exosomal circRNAs as diagnostic biomarkers for CAD. Methods. CircRNA expression levels in exosomes obtained from three plasma samples of CAD patients and three paired controls were analyzed using RNA sequencing. Exosomal circRNAs obtained in the profiling phase were then verified in two-center validation cohorts. Finally, the ability of exosomal circRNAs, adjusting for Framingham Heart Study (FHS) risk factors, was determined to discriminate between CAD patients and non-CAD controls. Results. 355 circRNAs were differentially expressed between these two groups: 164 were upregulated, and 191 were downregulated. Here, we selected the potential circRNAs (fold change>4, P<0.05) as candidate biomarkers for further validation. Our data showed that only hsa_circ_0005540 was significantly associated with CAD (P<0.0001). After adjustment for risk factors, hsa_circ_0005540 showed a high discriminatory power for CAD in ROC analyses (AUC=0.853; 95%confidence interval CI=0.799−0.906, P<0.001). Conclusion. Our results suggest that plasma exosomal hsa_circ_0005540 can be used as a promising diagnostic biomarker of CAD. |
Databáze: | OpenAIRE |
Externí odkaz: |